Molecular docking and dynamics reveal novel CDK6 inhibitors for targeted glioblastoma therapy
Glioblastoma multiform (GBM) is the most deadly type of primary CNS tumor and is linked to dysregulation of the CDK4/6 pathway, poor prognosis, and high rate of post-surgical recurrence.
Glioblastoma multiforme is the most lethal and fatal form of brain tumor hallmarked by significant molecular heterogeneity and dismal prognosis.
Developing CDK6‑targeting therapeutics is crucial because CDK4/6 dysregulation drives GBM progression and resistance to current therapies, yet no CDK6 inhibitors are approved for GBM treatment.
Evidence level: Számítógépes vagy elméleti. Modellből vagy adatbányászatból származó jel.
Related signals
- Diffuse Large B‑Cell Lymphoma – Global Clinical Trial Landscape (2024)
- Mantle‑Cell Lymphoma (MCL)
- Inhibition of autoantigen‑induced B‑cell receptor (BCR) internalization as a therapeutic strategy in diffuse large B cell lymphoma (DLBCL)
- Successful treatment of primary refractory DLBCL/HGBL - MYC/BCL2 transformed from FL using glofitamab: a case report
- Loncastuximab in high‑risk and heavily pre‑treated relapsed/refractory diffuse large B‑cell lymphoma: a real‑world analysis from 21 US centers